Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Learn how value tilts steer retirement portfolio index funds toward undervalued opportunities, balancing risk while pursuing higher long-term gains.
25,656 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Rigetti Computing shares slid in a choppy week as inflation jitters and noisy peers weighed on sentiment. This guide ...
This in-depth analysis breaks down Celanese’s 2025 earnings trajectory, highlighting drivers, margins, and cash flow....
Fluor dropped 26% and headlines lit up. But a solid long-term thesis for this EPC powerhouse requires more than a fla...
A decade of reinvested dividends can turn a modest $1,000 investment in Chevron into a much larger nest egg, even as ...
Figma posted impressive numbers in early 2026, yet the stock slumped. This article breaks down the drivers behind fig...
A single headline can move stock in moments, but the real story is rarely a simple one. This article dives into why a...
Meta’s latest quarter hints at more than just headline growth. This article explains why some investors excited about...
IMAX stock jumped this week as takeover chatter surfaced. This article breaks down the drivers behind the move, what ...
When Insperity s top executive buys a sizable stake, investors sit up. This article breaks down what insperity stock ...
Ark Invest's Cathie Wood is signaling a bold stance by scooping up Coinbase and Circle during a crypto sell-off. This...
Analysts are shifting their stance on Palantir, suggesting upside potential after a period of mixed momentum. This gu...